Login Register Cart 0
Review Article

抗NMDA受体脑炎：对男性患者的治疗功效和miRNA生物标志物

卷 27, 期 24, 2020

页: [4138 - 4151] 页: 14

弟呕挨: 10.2174/0929867325666180221142623

价格: $65

conference banner
摘要

背景：抗N-甲基-D-天冬氨酸（NMDA）受体脑炎是脑炎的一种急性形式。抗NMDA受体脑炎的治疗方法通常包括类固醇，静脉注射免疫球蛋白，血浆置换，血浆清除，利妥昔单抗，环磷酰胺和肿瘤切除。 目的：我们旨在比较静脉注射免疫球蛋白，血浆置换，血浆清除，利妥昔单抗或环磷酰胺治疗对无肿瘤的男性抗NMDA受体脑炎患者的疗效，并探讨该疾病的潜在生物标志物。 方法：采用Fisher精确检验和列联表分析法对43例男性和76例女性患者的治疗效果进行分析。另外，采用分层树法分析了男性和女性患者治疗效果的差异。 结果：测试男性患者血浆置换的功效率是否大于阈值的p值与其他两种治疗的p值显着不同。此外，分层树法表明，男性和女性患者与早期康复相关的治疗策略是不同的。 结论：结果表明，对于没有肿瘤的男性患者，血浆置换（或血浆清除）的疗效率不逊于静脉注射免疫球蛋白和利妥昔单抗（或环磷酰胺）。另外，吸引B细胞的C-X-C基序趋化因子13（CXCL13）和microRNA let-7b具有成为抗NMDA受体脑炎的治疗反应生物标志物的潜力。除非它们不是其他自身免疫性脑炎的生物标志物，否则它们可能不是该脑炎有用的预后生物标志物。

关键词: 抗NMDA受体脑炎，免疫疗法，有效率，治疗，趋化因子13，microRNA。

« Previous
[1]
Srebro, D.; Vučković, S.; Milovanović, A.; Košutić, J.; Vujović, K.S.; Prostran, M. Magnesium in pain research: state of the art. Curr. Med. Chem., 2017, 24(4), 424-434.
[PMID: 27978803]
[2]
Dalmau, J.; Tüzün, E.; Wu, H.Y.; Masjuan, J.; Rossi, J.E.; Voloschin, A.; Baehring, J.M.; Shimazaki, H.; Koide, R.; King, D.; Mason, W.; Sansing, L.H.; Dichter, M.A.; Rosenfeld, M.R.; Lynch, D.R. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann. Neurol., 2007, 61(1), 25-36.
[http://dx.doi.org/10.1002/ana.21050] [PMID: 17262855]
[3]
Dalmau, J.; Gleichman, A.J.; Hughes, E.G.; Rossi, J.E.; Peng, X.; Lai, M.; Dessain, S.K.; Rosenfeld, M.R.; Balice-Gordon, R.; Lynch, D.R. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol., 2008, 7(12), 1091-1098.
[http://dx.doi.org/10.1016/S1474-4422(08)70224-2] [PMID: 18851928]
[4]
Wang, H. Anti-NMDA receptor encephalitis and vaccination. Int. J. Mol. Sci., 2017, 18(1)E193
[http://dx.doi.org/10.3390/ijms18010193] [PMID: 28106787]
[5]
Titulaer, M.J.; McCracken, L.; Gabilondo, I.; Armangué, T.; Glaser, C.; Iizuka, T.; Honig, L.S.; Benseler, S.M.; Kawachi, I.; Martinez-Hernandez, E.; Aguilar, E.; Gresa-Arribas, N.; Ryan-Florance, N.; Torrents, A.; Saiz, A.; Rosenfeld, M.R.; Balice-Gordon, R.; Graus, F.; Dalmau, J. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol., 2013, 12(2), 157-165.
[http://dx.doi.org/10.1016/S1474-4422(12)70310-1] [PMID: 23290630]
[6]
Shah, N.N. Antibody based therapies in acute leukemia. Curr. Drug Targets, 2017, 18(3), 257-270.
[http://dx.doi.org/10.2174/1389450117666160905091459] [PMID: 27593687]
[7]
Witkowska, M.; Smolewski, P. Development of Anti-CD20 antigen-targeting therapies for B-cell lymphoproliferative malignancies - the state of the art. Curr. Drug Targets, 2016, 17(9), 1072-1082.
[http://dx.doi.org/10.2174/1389450116666150907105306] [PMID: 26343115]
[8]
Sebastiani, M.; Giuggioli, D.; Colaci, M.; Fallahi, P.; Gragnani, L.; Antonelli, A.; Zignego, A.L.; Ferri, C. HCV-related rheumatic manifestations and therapeutic strategies. Curr. Drug Targets, 2017, 18(7), 803-810.
[http://dx.doi.org/10.2174/1389450116666150907103622] [PMID: 26343108]
[9]
Giuggioli, D.; Sebastiani, M.; Colaci, M.; Fallahi, P.; Gragnani, L.; Zignego, A.L.; Antonelli, A.; Ferri, C. Treatment of HCV-related mixed cryoglobulinemia. Curr. Drug Targets, 2017, 18(7), 794-802.
[http://dx.doi.org/10.2174/1389450116666150825112105] [PMID: 26302805]
[10]
Risitano, A.M. Withdrawn: aplastic anemia: alternative immunosuppressive treatments and eltrombopag. A report from the 2014 EBMT educational meeting from the severe aplastic anaemia and infectious diseases working parties. Curr. Drug Targets, 2015..
[PMID: 25619749]
[11]
Wang, H. Efficacies of treatments for anti-NMDA receptor encephalitis. Front. Biosci., 2016, 21, 651-663.
[http://dx.doi.org/10.2741/4412] [PMID: 26709797]
[12]
Rosenfeld, M.R. Antibody-mediated central nervous system diseases: disease recognition and treatment challenges. Clin. Exp. Immunol., 2014, 178(Suppl. 1), 30-32.
[http://dx.doi.org/10.1111/cei.12501] [PMID: 25546752]
[13]
Li, H.; Zhai, Z.; Qu, X.; Xu, J.; Qin, A.; Dai, K. MicroRNAs as potential targets for treatment of osteoclast-related diseases. Curr. Drug Targets, 2018, 19(5), 422-431.
[http://dx.doi.org/10.2174/1389450117666160502144329] [PMID: 27138766]
[14]
Lee, C.H.; Kim, J.H.; Lee, S.W. The role of MicroRNA in pathogenesis and as markers of HCV chronic infection. Curr. Drug Targets, 2017, 18(7), 756-765.
[http://dx.doi.org/10.2174/1389450117666160401125213] [PMID: 27033188]
[15]
Hang, P.; Guo, J.; Sun, C.; Du, Z. MicroRNAs as candidate drug targets for cardiovascular diseases. Curr. Drug Targets, 2017, 18(4), 463-472.
[http://dx.doi.org/10.2174/1389450117666160301101221] [PMID: 26926467]
[16]
Rocic, P. Can microRNAs be biomarkers or targets for therapy of ischemic coronary artery disease in metabolic syndrome? Curr. Drug Targets, 2017, 18(15), 1722-1732.
[http://dx.doi.org/10.2174/1389450117666160201113734] [PMID: 26844562]
[17]
Castro, R.E.; Rodrigues, C.M.P. Cell death and microRNAs in cholestatic liver diseases: update on potential therapeutic applications. Curr. Drug Targets, 2017, 18(8), 921-931.
[http://dx.doi.org/10.2174/1389450116666151019102358] [PMID: 26477457]
[18]
Leypoldt, F.; Höftberger, R.; Titulaer, M.J.; Armangue, T.; Gresa-Arribas, N.; Jahn, H.; Rostásy, K.; Schlumberger, W.; Meyer, T.; Wandinger, K.P.; Rosenfeld, M.R.; Graus, F.; Dalmau, J. Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response. JAMA Neurol., 2015, 72(2), 180-186.
[http://dx.doi.org/10.1001/jamaneurol.2014.2956] [PMID: 25436993]
[19]
Zhang, J.; Xu, X.; Zhao, S.; Gong, Z.; Liu, P.; Guan, W.; He, X.; Wang, T.; Peng, T.; Teng, J.; Jia, Y. The expression and significance of the plasma let-7 family in anti-N-methyl-D-aspartate receptor encephalitis. J. Mol. Neurosci., 2015, 56(3), 531-539.
[http://dx.doi.org/10.1007/s12031-015-0489-6] [PMID: 25603816]
[20]
Liba, Z.; Kayserova, J.; Elisak, M.; Marusic, P.; Nohejlova, H.; Hanzalova, J.; Komarek, V.; Sediva, A. Anti-N-methyl-D-aspartate receptor encephalitis: the clinical course in light of the chemokine and cytokine levels in cerebrospinal fluid. J. Neuroinflammation, 2016, 13(1), 55.
[http://dx.doi.org/10.1186/s12974-016-0507-9] [PMID: 26941012]
[21]
Hachiya, Y.; Uruha, A.; Kasai-Yoshida, E.; Shimoda, K.; Satoh-Shirai, I.; Kumada, S.; Kurihara, E.; Suzuki, K.; Ohba, A.; Hamano, S.; Sakuma, H. Rituximab ameliorates anti-N-methyl-D-aspartate receptor encephalitis by removal of short-lived plasmablasts. J. Neuroimmunol., 2013, 265(1-2), 128-130.
[http://dx.doi.org/10.1016/j.jneuroim.2013.09.017] [PMID: 24183642]
[22]
Pham, H.P.; Daniel-Johnson, J.A.; Stotler, B.A.; Stephens, H.; Schwartz, J. Therapeutic plasma exchange for the treatment of anti-NMDA receptor encephalitis. J. Clin. Apher., 2011, 26(6), 320-325.
[http://dx.doi.org/10.1002/jca.20311] [PMID: 21898576]
[23]
Zhong, X.; Wang, H.; Dai, Y.; Wu, A.; Bao, J.; Xu, W.; Cheng, C.; Lu, Z.; Qiu, W.; Hu, X. Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica. J. Neuroimmunol., 2011, 240-241, 104-108.
[http://dx.doi.org/10.1016/j.jneuroim.2011.10.001] [PMID: 22036953]
[24]
Khademi, M.; Kockum, I.; Andersson, M.L.; Iacobaeus, E.; Brundin, L.; Sellebjerg, F.; Hillert, J.; Piehl, F.; Olsson, T. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult. Scler., 2011, 17(3), 335-343.
[http://dx.doi.org/10.1177/1352458510389102] [PMID: 21135023]
[25]
Karthikeyan, A.; Patnala, R.; Jadhav, S.P.; Eng-Ang, L.; Dheen, S.T. MicroRNAs: key players in microglia and astrocyte mediated inflammation in CNS pathologies. Curr. Med. Chem., 2016, 23(30), 3528-3546.
[http://dx.doi.org/10.2174/0929867323666160814001040] [PMID: 27528056]
[26]
Hsieh, W.J.; Lin, F.M.; Huang, H.D.; Wang, H. Investigating microRNA-target interaction-supported tissues in human cancer tissues based on miRNA and target gene expression profiling. PLoS One, 2014, 9(4)e95697
[http://dx.doi.org/10.1371/journal.pone.0095697] [PMID: 24756070]
[27]
Calin, G.A.; Sevignani, C.; Dumitru, C.D.; Hyslop, T.; Noch, E.; Yendamuri, S.; Shimizu, M.; Rattan, S.; Bullrich, F.; Negrini, M.; Croce, C.M. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA, 2004, 101(9), 2999-3004.
[http://dx.doi.org/10.1073/pnas.0307323101] [PMID: 14973191]
[28]
Beatty, C.W.; Creutzfeldt, C.J.; Davis, A.P.; Hoffer, Z.; Khot, S.P. The diagnostic conundrum and treatment dilemma of a patient with a rapidly progressive encephalopathy. Neurohospitalist, 2014, 4(1), 34-41.
[http://dx.doi.org/10.1177/1941874413496792] [PMID: 24381709]
[29]
Luca, N.; Daengsuwan, T.; Dalmau, J.; Jones, K.; deVeber, G.; Kobayashi, J.; Laxer, R.M.; Benseler, S.M. Anti-N-methyl-D-aspartate receptor encephalitis: a newly recognized inflammatory brain disease in children. Arthritis Rheum., 2011, 63(8), 2516-2522.
[http://dx.doi.org/10.1002/art.30437] [PMID: 21547896]
[30]
Wong-Kisiel, L.C.; Ji, T.; Renaud, D.L.; Kotagal, S.; Patterson, M.C.; Dalmau, J.; Mack, K.J. Response to immunotherapy in a 20-month-old boy with anti-NMDA receptor encephalitis. Neurology, 2010, 74(19), 1550-1551.
[http://dx.doi.org/10.1212/WNL.0b013e3181dd41a1] [PMID: 20458074]
[31]
Marques, I.B.; Teotónio, R.; Cunha, C.; Bento, C.; Sales, F. Anti-NMDA receptor encephalitis presenting with total insomnia--a case report. J. Neurol. Sci., 2014, 336(1-2), 276-280.
[http://dx.doi.org/10.1016/j.jns.2013.10.034] [PMID: 24210076]
[32]
Cantari;n-Extremera, V.; Duat-Rodri;guez, A.; González-Gutiérrez-Solana, L.; López-Mari;n, L.; Armangue, T. Clinical case of anti-N-methyl-D-aspartate receptor encephalitis in an 8-month-old patient with hyperkinetic movement disorder. Pediatr. Neurol., 2013, 48(5), 400-402.
[http://dx.doi.org/10.1016/j.pediatrneurol.2012.12.032] [PMID: 23583060]
[33]
Suzuki, H.; Kitada, M.; Ueno, S.; Tanaka, K.; Kusunoki, S. Anti-NMDAR encephalitis preceded by dura mater lesions. Neurol. Sci., 2013, 34(6), 1021-1022.
[http://dx.doi.org/10.1007/s10072-012-1169-8] [PMID: 22851287]
[34]
Raha, S.; Gadgil, P.; Sankhla, C.; Udani, V. Nonparaneoplastic anti-N-methyl-D-aspartate receptor encephalitis: a case series of four children. Pediatr. Neurol., 2012, 46(4), 246-249.
[http://dx.doi.org/10.1016/j.pediatrneurol.2012.01.012] [PMID: 22490772]
[35]
Takeda, A.; Shimada, H.; Tamura, A.; Yasui, M.; Yamamoto, K.; Itoh, K.; Ataka, S.; Tanaka, S.; Ohsawa, M.; Hatsuta, H.; Hirano, M.; Sakamoto, H.; Ueno, S.; Nakamura, Y.; Tsutada, T.; Miki, T. A case of anti-N-methyl-d-aspartate receptor encephalitis with multiple sclerosis-like demyelinated lesions. Mult. Scler. Relat. Disord., 2014, 3(3), 391-397.
[http://dx.doi.org/10.1016/j.msard.2013.09.005] [PMID: 25876479]
[36]
Aguiar de Sousa, D.; Lobo, P.P.; Caldas, A.C.; Coelho, M.; Albuquerque, L. Pure ataxia associated with N-methyl-D-aspartate receptor antibodies. Parkinsonism Relat. Disord., 2014, 20(5), 568-569.
[http://dx.doi.org/10.1016/j.parkreldis.2014.02.015] [PMID: 24637122]
[37]
Di Capua, D.; Garci;a-Ptacek, S.; Garci;a-Garci;a, M.E.; Abarrategui, B.; Porta-Etessam, J.; Garci;a-Morales, I. Extreme delta brush in a patient with anti-NMDAR encephalitis. Epi. Disord., 2013, 15(4), 461-464.
[http://dx.doi.org/10.1684/epd.2013.0622]
[38]
Ramanathan, S.; Mohammad, S.S.; Brilot, F.; Dale, R.C. Autoimmune encephalitis: recent updates and emerging challenges. J. Clin. Neurosci., 2014, 21(5), 722-730.
[http://dx.doi.org/10.1016/j.jocn.2013.07.017] [PMID: 24246947]
[39]
Dale, R.C.; Pillai, S.; Brilot, F. Cerebrospinal fluid CD19(+) B-cell expansion in N-methyl-D-aspartate receptor encephalitis. Dev. Med. Child Neurol., 2013, 55(2), 191-193.
[http://dx.doi.org/10.1111/dmcn.12036] [PMID: 23151040]
[40]
Finné Lenoir, X.; Sindic, C.; van Pesch, V.; El Sankari, S.; de Tourtchaninoff, M.; Denays, R.; Hantson, P. Anti-N-methyl-D-aspartate receptor encephalitis with favorable outcome despite prolonged status epilepticus. Neurocrit. Care, 2013, 18(1), 89-92.
[http://dx.doi.org/10.1007/s12028-012-9788-8] [PMID: 23090840]
[41]
Shah, R.; Veerapandiyan, A.; Winchester, S.; Gallentine, W.; Mikati, M.A. Two patients with an anti-N-methyl-D-aspartate receptor antibody syndrome-like presentation and negative results of testing for autoantibodies. Pediatr. Neurol., 2011, 45(6), 412-416.
[http://dx.doi.org/10.1016/j.pediatrneurol.2011.09.012] [PMID: 22115008]
[42]
Uruha, A.; Kitazawa, Y.; Kuroda, M.; Tanaka, K.; Koide, R. Anti-NMDAR encephalitis in small-cell lung cancer: a case report. Clin. Neurol. Neurosurg., 2012, 114(3), 260-261.
[http://dx.doi.org/10.1016/j.clineuro.2011.10.015] [PMID: 22047651]
[43]
Frechette, E.S.; Zhou, L.; Galetta, S.L.; Chen, L.; Dalmau, J. Prolonged follow-up and CSF antibody titers in a patient with anti-NMDA receptor encephalitis. Neurology, 2011, 76(7)(Suppl. 2), S64-S66.
[http://dx.doi.org/10.1212/WNL.0b013e31820c34de] [PMID: 21321356]
[44]
Day, G.S.; High, S.M.; Cot, B.; Tang-Wai, D.F. Anti-NMDA-receptor encephalitis: case report and literature review of an under-recognized condition. J. Gen. Intern. Med., 2011, 26(7), 811-816.
[http://dx.doi.org/10.1007/s11606-011-1641-9] [PMID: 21318640]
[45]
Houtrow, A.J.; Bhandal, M.; Pratini, N.R.; Davidson, L.; Neufeld, J.A. The rehabilitation of children with anti-N methyl-D-aspartate-receptor encephalitis: a case series. Am.J.Phys Med Rehabil., 2012, 91(5), 435-441.
[http://dx.doi.org/10.1097/PHM.0b013e3182465da6] [PMID: 22415341]
[46]
Viaccoz, A.; Desestret, V.; Ducray, F.; Picard, G.; Cavillon, G.; Rogemond, V.; Antoine, J.C.; Delattre, J.Y.; Honnorat, J. Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology, 2014, 82(7), 556-563.
[http://dx.doi.org/10.1212/WNL.0000000000000126] [PMID: 24443452]
[47]
Liu, J.; Wang, D.; Xiong, Y.; Liu, B.; Liu, M. Anti-NMDAR encephalitis of 11 Cases in China - detailed clinical, laboratory and imagiological description. Eur. Neurol., 2015, 74(1-2), 73-78.
[http://dx.doi.org/10.1159/000435953] [PMID: 26277996]
[48]
Armangue, T.; Moris, G.; Cantari;n-Extremera, V.; Conde, C.E.; Rostasy, K.; Erro, M.E.; Portilla-Cuenca, J.C.; Turón-Viñas, E.; Málaga, I.; Muñoz-Cabello, B.; Torres Torres, C.; Llufriu, S.; González-Gutiérrez-Solana, L.; González, G.; Casado-Naranjo, I.; Rosenfeld, M.; Graus, F.; Dalmau, J. Spanish Prospective Multicentric Study of Autoimmunity in Herpes Simplex Encephalitis. Autoimmune post-herpes simplex encephalitis of adults and teenagers. Neurology, 2015, 85(20), 1736-1743.
[http://dx.doi.org/10.1212/WNL.0000000000002125] [PMID: 26491084]
[49]
DeSena, A.D.; Greenberg, B.M.; Graves, D. Three phenotypes of anti-N-methyl-D-aspartate receptor antibody encephalitis in children: prevalence of symptoms and prognosis. Pediatr. Neurol., 2014, 51(4), 542-549.
[http://dx.doi.org/10.1016/j.pediatrneurol.2014.04.030] [PMID: 25070939]
[50]
Venâncio, P.; Brito, M.J.; Pereira, G.; Vieira, J.P. Anti-N-methyl-D-aspartate receptor encephalitis with positive serum antithyroid antibodies, IgM antibodies against mycoplasma pneumoniae and human herpesvirus 7 PCR in the CSF. Pediatr. Infect. Dis. J., 2014, 33(8), 882-883.
[http://dx.doi.org/10.1097/INF.0000000000000408] [PMID: 25222311]
[51]
Barros, P.; Brito, H.; Ferreira, P.C.; Ramalheira, J.; Lopes, J.; Rangel, R.; Temudo, T.; Figueiroa, S. Resective surgery in the treatment of super-refractory partial status epilepticus secondary to NMDAR antibody encephalitis. Eur. J. Paediatr. Neurol., 2014, 18(3), 449-452.
[http://dx.doi.org/10.1016/j.ejpn.2014.01.013] [PMID: 24594428]
[52]
Tatencloux, S.; Chretien, P.; Rogemond, V.; Honnorat, J.; Tardieu, M.; Deiva, K. Intrathecal treatment of anti-N-Methyl-D-aspartate receptor encephalitis in children. Dev. Med. Child Neurol., 2015, 57(1), 95-99.
[http://dx.doi.org/10.1111/dmcn.12545] [PMID: 25040285]
[53]
Kadoya, M.; Kadoya, A.; Onoue, H.; Ikewaki, K.; Kaida, K. An atypical case of anti-NMDA receptor encephalitis: predominant parkinsonism and persisting micrographia without oro-facial dyskinesia. Intern. Med., 2015, 54(15), 1927-1932.
[http://dx.doi.org/10.2169/internalmedicine.54.3757] [PMID: 26234239]
[54]
Kim, H.; Ryu, H.; Kang, J.K. Anti-NMDA receptor antibody encephalitis presenting with unilateral non-convulsive status epilepticus in a male patient. J. Epilepsy Res., 2015, 5(1), 17-19.
[http://dx.doi.org/10.14581/jer.15004] [PMID: 26157669]
[55]
Loughan, A.R.; Allen, A.; Perna, R.; Malkin, M.G. Anti-N-Methyl-D-Aspartate receptor encephalitis: a review and neuropsychological case study. Clin. Neuropsychol., 2016, 30(1), 150-163.
[http://dx.doi.org/10.1080/13854046.2015.1132772] [PMID: 26998574]

Rights & Permissions Print Cite
Article Metrics
45
5
© 2024 Bentham Science Publishers | Privacy Policy